The District of Delaware entered final judgment in favor of Astellas Pharma Inc. in this action alleging that Ascent Pharmaceuticals Inc.'s abbreviated new drug application infringes claims of its Myrbetriq® brand product, which is indicated for treatment of overactive bladder. The court rejected Ascent’s invalidity defense and found in favor of Astellas on its infringement claim.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.